Cyclin L1 rabbit pAb

• Background :

  Alternative products:Ccnl1 is an immediate-early gene with independently regulated isoforms, domain:Contains a RS region (arginine-serine dipeptide repeat) within the C-terminal domain which is the hallmark of the SR family of splicing factors. This region probably plays a role in protein-protein interactions., function:Transcriptional regulator which participates in regulating the pre-mRNA splicing process. Seems to be involved in the regulation of RNA polymerase II (pol II) . Functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC) . Inhibited by the CDK-specific inhibitor p21., miscellaneous:CCNL1 is amplified in several HNSCC. May play a critical role in the formation of loco-regional metastases and an unfavorable clinical outcome of HNSCC., sequence caution:Probable cloning artifact., similarity:Belongs to the cyclin family. Cyclin L subfamily., subcellular location:More specifically found in nuclear intrachromatin granules clusters (IGC), also called nuclear speckles, which are storage compartments for nuclear proteins involved in mRNA processing., subunit:Interacts with POLR2A via its hyperphosphorylated C-terminal domain (CTD) (By similarity) . Interacts with CDC2L1 or CDC2L2, and SFRS2., tissue specificity:Ubiquitous with higher level in thymus. Overexpression in primary tumors of head and neck squamous cell carcinomas (HNSCC) .

• Description :

  Alternative products: Ccnl1 is an immediate-early gene with independently regulated isoforms, Domain: Contains a RS region (arginine-serine dipeptide repeat) within the C-terminal domain which is the hallmark of the SR family of splicing factors. This region probably plays a role in protein-protein interactions. function: Transcriptional regulator which participates in regulating the pre-mRNA splicing process. Seems to be involved in the regulation of RNA polymerase II (pol II). Functions in association with cyclin-dependent kinases (CDKs) and has a role in the second step of splicing. May be a candidate proto-oncogene in head and neck squamous cell carcinomas (HNSCC). Inhibited by the CDK-specific inhibitor p21. miscellaneous: CCNL1 is amplified in several HNSCC. May play a critical role in the formation of loco-regional metastases and an unfavorable clinical outcome of HNSCC. sequence Caution: Probable cloning artifact. similarity: Belongs to the cyclin family. Cyclin L subfamily. subcellular location: More specifically found in nuclear intrachromatin granules clusters (IGC), also called nuclear speckles, which are storage compartments for nuclear proteins involved in mRNA processing. subunit: Interacts with POLR2A via its hyperphosphorylated C-terminal domain (CTD) (By similarity). Interacts with CDC2L1 or CDC2L2, and SFRS2. tissue specificity: Ubiquitous with higher level in thymus. Overexpression in primary tumors of head and neck squamous cell carcinomas (HNSCC).

• Product Name Alternative :

  CCNL1; BM-001; Cyclin-L1; Cyclin-L

• UniProt :

  Q9UK58

• Swiss Prot :

  Q9UK58

• Reactivity :

  Human; Mouse; Rat

• Immunogen :

  The antiserum was produced against synthesized peptide derived from human Cyclin L1. AA range:461-510

• Target :

  Cyclin L1

• Clonality :

  Polyclonal

• Source :

  Rabbit

• Applications :

  WB; IHC; IF; ELISA

• Concentration :

  1 mg/ml

• Dilution :

  Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications.

• Buffer :

  -20°C/1 year

• Molecular Weight :

  60kD

• Storage Conditions :

  -20°C/1 year

• Observed Molecular Weight :

  60kD

• Fragment :

  IgG

• Subcellular Location :

  Nucleus speckle . Nucleus, nucleoplasm . Found in nuclear intrachromatin granules clusters (IGC), also called nuclear speckles, which are storage compartments for nuclear proteins involved in mRNA processing. .

• Other Product Names :

  CCNL1; BM-001; Cyclin-L1; Cyclin-L

• Gene ID (Human) :

  57018